Phase I/II – First Administration

453 trials 190 recruiting

Filter these 453 trials by condition, country, sponsor and more.

Open in Search →

Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® Pending

2024-518307-22-01 Surgical wound infection/dehiscence caused by S. aureus
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies Pending

2024-518326-32-00 Patients with advanced solid malignancies that have pro
A multicenter double-blind, randomized, placebo-controlled phase I/II study to determine the safety, tolerability, potential efficacy and do… Pending

2024-518501-17-00 Peanut allergy
NEurotrophins Mimetic compound for the treatment of diabetic foot UlcerS Pending

2024-519405-35-00 Diabetic Foot Ulcer
CLINICAL TRIAL FOR THE PREVENTION OF CYTOMEGALOVIRUS INFECTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH NO AVAILABLE TREA… Pending

2024-520020-28-00 Cytomegalovirus infection post allogeneic allogeneic HL
A study to learn how safe AZD6621 is, how well it works, and how it moves throughout the body over time, in adult male participants with Met… Pending

2025-520626-37-00 Metastatic Prostate Cancer
A phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokin… Pending

2025-521164-36-00 Patients with relapsed/refractory advanced/metastatic o
Clinical trial to assess the safety and tolerability of TP-122A for the treatment of ventilator-associated pneumonia. Pending

2025-521533-85-00 Ventilator-Associated Pneumonia
Phase 1/2 study to investigate the safety and preliminary efficacy of GSK5460025 alone or in combination with other anti-cancer agents in dM… Pending

2025-522318-21-00 Neoplasms, Colorectal
A First-in-Human Trial of DS3790a in Participants with Hematological Malignancies. Pending

2025-522595-87-00 Hematological Malignancies
A two-part study: open label, dose escalation phase aimed to evaluate the safety and tolerability of two different doses of allogeneic fibro… Pending

2025-522647-17-00 Refractory wounds
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1) Pending

2025-522944-41-00 Solid Tumours
Study on the effect of 6qc-ICG on the skin of healthy volunteers and in patients with breast cancer during surgeries. Pending

2025-523166-24-00 Breast cancer
A First-In-Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination with Cemiplimab Works in Adult Participan… Pending

2025-523399-22-00 Advanced Solid Tumours
A Phase 1/2a Study of BMS-986523 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Malignancies Pending

2025-523547-35-00 Advanced Solid Tumor Malignancies
A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, a… Pending

2025-523590-42-00 Locally Advanced or Metastatic Solid Tumors
REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Res… Pending

2025-524232-20-00 Patients with poor prognostic ovarian cancers based on
The RJVA-001 First in Human Trial in Adults with Inadequately Controlled Type 2 Diabetes. Pending

2025-524438-24-00 Type 2 Diabetes
Gene Therapy Trial for OTOF-mediated Hearing Loss Pending

2023-505128-76-00 Otoferlin gene-mediated hearing loss
ATA-200 gene therapy trial in patients with LGMDR5 Pending

2023-506440-16-00 limb-girdle muscular dystrophy type R5 (previously name
An adaptive open-label multicentre phase 1/2 trial, to determine the recommended phase 2 dose of CCTx-001, and to assess safety, tolerabilit… Pending

2023-506865-71-00 Relapsed/Refractory Acute Myeloid Leukemia (AML)
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With … Pending

2024-513579-42-00 Type 1 Myotonic Dystrophy
Long-term Follow-up (LTFU) Study of Participants in any iECURE Protocol Using an Investigational Product (IP) Pending

2024-514190-21-00 Ornithine Transcarbamylase Deficiency (OTC)
Assess effect and safety of intra-arterial autologous mesoangioblast administration to the upper arm of m.3243A>G mutation carriers Pending

2024-515129-27-00 m.3243A>G mutation causing mitochondrial myopathy